Under one in 10 patients who could benefit from weight-loss injections like Wegovy can access them, states the global health agency as it releases its initial advice on the drugs.
Considering over a billion individuals worldwide currently living with obesity, it is urging increased and just access to this class of drugs.
According to projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be managed with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are key hurdles to universal access to the jabs that can help people shift substantial body mass, notes the organization.
Weight-Loss Drug Supply Crisis
Despite the current most optimistic scenario, the supply of these medications could only cover around 100 million people – less than 10% of those who need them, according to the health organization.
The recommendation urges governments and firms to increase access, by approaches including patent sharing.
A patent on the active ingredient – the main ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
How Obesity Drugs Function
These medications replicate a natural hormone to delay gastric emptying, curb appetite and increase satiety so individuals consume fewer calories.
Individuals commonly start to lose weight in the initial weeks of commencing the once-weekly jabs.
Studies indicates users may regain a significant portion a year later of discontinuing the treatment, because their normal appetite return.
To be carrying excess weight increases your likelihood for developing health problems, like diabetes, heart disease, brain attack, and some malignancies.
Obesity concerns people in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.
